French orthopedic implants maker Implanet's nine-month revenue jumps, partly on strong US momentum

By Reuters News


Overview

  • France orthopedic implants maker's nine-month 2026 revenue grew 21% yr/yr to €10.6 mln

  • Q3 2026 revenue rose 18% yr/yr to €3.44 mln

  • Growth driven by expansion in Spine Implants and Medical Equipment, strong US momentum


Outlook

  • Company plans to reinforce U.S. commercial team and accelerate rollout of JAZZ and co-developed products

  • Implanet aims to expand JSS and Sanyou Medical product lines in France, U.S. and internationally

  • Company to launch SMTP Quntas range and expand distribution of Sanyou Medical surgical technologies


Result Drivers

  • JSS SYSTEM SALES - Co said doubling sales of new JSS hybrid posterior fixation system boosted Spine Implants revenue

  • MEDICAL EQUIPMENT - Continued rollout of SMTP ultrasonic scalpel drove Medical Equipment revenue higher

  • US GROWTH - Co said strong US sales contributed significantly to overall revenue increase


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Revenue

EUR 10.6 mln


Reuters Recommended Reads

  • Oct 12 - France's LVMH nine-month revenue slips amid weak Q3 demand in China


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.